Loading…
Can selenium be a modifier of cancer risk in CHEK2 mutation carriers?
Selenium is an essential trace element for humans, playing an important role in various major metabolic pathways. Selenium helps to protect the body from the poisonous effects of heavy metals and other harmful substances. Medical studies have provided evidence of selenium supplementation in preventi...
Saved in:
Published in: | Mutagenesis 2013-11, Vol.28 (6), p.625-629 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c359t-e7dbb411a93ab4e8da264cd0197cfa7b1f5866f547d3472145f3d0159bad822f3 |
---|---|
cites | cdi_FETCH-LOGICAL-c359t-e7dbb411a93ab4e8da264cd0197cfa7b1f5866f547d3472145f3d0159bad822f3 |
container_end_page | 629 |
container_issue | 6 |
container_start_page | 625 |
container_title | Mutagenesis |
container_volume | 28 |
creator | Gupta, Satish Jaworska-Bieniek, Katarzyna Lubiński, Jan Jakubowska, Anna |
description | Selenium is an essential trace element for humans, playing an important role in various major metabolic pathways. Selenium helps to protect the body from the poisonous effects of heavy metals and other harmful substances. Medical studies have provided evidence of selenium supplementation in preventing certain cancers. Low and too high selenium (Se) status correlates with increased risk of e.g. lung, larynx, colorectal and prostate cancers. A higher level of selenium and supplementation with selenium has been shown to be associated with substantially reduced cancer mortality. Selenium exerts its biological roles through selenoproteins, which are involved in oxidoreductions, redox signalling, antioxidant defence, thyroid hormone metabolism and immune responses. Checkpoint kinase 2 (CHEK2) is an important signal transducer of cellular responses to DNA damage and acts as a tumour suppressor gene. Mutations in the CHEK2 gene have been shown to be associated with increased risks of several cancers. Four common mutations in CHEK2 gene (1100delC, IVS2+1G>A, del5395 and I157T) have been identified in the Polish population. Studies have provided evidence that CHEK2-truncating and/or missense mutations are associated with increased risk of breast, prostate, thyroid, colon and kidney cancers. The variability in penetrance and cancer expression in CHEK2 mutation carriers can probably be explained by the influence of other genetic or environmental factors. One of the possible candidates is Se, which together with genetic variations in selenoprotein genes may influence susceptibility to cancer risk. |
doi_str_mv | 10.1093/mutage/get050 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1492620453</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/mutage/get050</oup_id><sourcerecordid>1492620453</sourcerecordid><originalsourceid>FETCH-LOGICAL-c359t-e7dbb411a93ab4e8da264cd0197cfa7b1f5866f547d3472145f3d0159bad822f3</originalsourceid><addsrcrecordid>eNqFkD1PwzAURS0EoqUwsiKPLKHP38mEUFQoohILzJGT2JUhiYudDPz7pkqBkek96R7dKx2ErgncEcjYsh16vTXLrelBwAmaEy55wlLgp2gOVKokZULN0EWMHwBEUQnnaEY5AQmg5miV6w5H05jODS0uDda49bWzzgTsLa50V41fcPETuw7n69ULxYfJ3vluTEMYwXh_ic6sbqK5Ot4Fen9cveXrZPP69Jw_bJKKiaxPjKrLkhOiM6ZLbtJaU8mrGkimKqtVSaxIpbSCq5pxRQkXlo2pyEpdp5RatkC3U-8u-K_BxL5oXaxM0-jO-CEWhGdUUuCCjWgyoVXwMQZji11wrQ7fBYHiYK6YzBWTuZG_OVYPZWvqX_pH1d-2H3b_dO0BInh35Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1492620453</pqid></control><display><type>article</type><title>Can selenium be a modifier of cancer risk in CHEK2 mutation carriers?</title><source>Oxford Journals Online</source><creator>Gupta, Satish ; Jaworska-Bieniek, Katarzyna ; Lubiński, Jan ; Jakubowska, Anna</creator><creatorcontrib>Gupta, Satish ; Jaworska-Bieniek, Katarzyna ; Lubiński, Jan ; Jakubowska, Anna</creatorcontrib><description>Selenium is an essential trace element for humans, playing an important role in various major metabolic pathways. Selenium helps to protect the body from the poisonous effects of heavy metals and other harmful substances. Medical studies have provided evidence of selenium supplementation in preventing certain cancers. Low and too high selenium (Se) status correlates with increased risk of e.g. lung, larynx, colorectal and prostate cancers. A higher level of selenium and supplementation with selenium has been shown to be associated with substantially reduced cancer mortality. Selenium exerts its biological roles through selenoproteins, which are involved in oxidoreductions, redox signalling, antioxidant defence, thyroid hormone metabolism and immune responses. Checkpoint kinase 2 (CHEK2) is an important signal transducer of cellular responses to DNA damage and acts as a tumour suppressor gene. Mutations in the CHEK2 gene have been shown to be associated with increased risks of several cancers. Four common mutations in CHEK2 gene (1100delC, IVS2+1G>A, del5395 and I157T) have been identified in the Polish population. Studies have provided evidence that CHEK2-truncating and/or missense mutations are associated with increased risk of breast, prostate, thyroid, colon and kidney cancers. The variability in penetrance and cancer expression in CHEK2 mutation carriers can probably be explained by the influence of other genetic or environmental factors. One of the possible candidates is Se, which together with genetic variations in selenoprotein genes may influence susceptibility to cancer risk.</description><identifier>ISSN: 0267-8357</identifier><identifier>EISSN: 1464-3804</identifier><identifier>DOI: 10.1093/mutage/get050</identifier><identifier>PMID: 24106007</identifier><language>eng</language><publisher>UK: Oxford University Press</publisher><subject>Checkpoint Kinase 2 - genetics ; Checkpoint Kinase 2 - metabolism ; Dietary Supplements ; Humans ; Mutation ; Neoplasms - enzymology ; Neoplasms - genetics ; Neoplasms - prevention & control ; Selenium - administration & dosage ; Selenium - physiology ; Selenoproteins - metabolism ; Signal Transduction</subject><ispartof>Mutagenesis, 2013-11, Vol.28 (6), p.625-629</ispartof><rights>The Author 2013. Published by Oxford University Press on behalf of the UK Environmental Mutagen Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c359t-e7dbb411a93ab4e8da264cd0197cfa7b1f5866f547d3472145f3d0159bad822f3</citedby><cites>FETCH-LOGICAL-c359t-e7dbb411a93ab4e8da264cd0197cfa7b1f5866f547d3472145f3d0159bad822f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24106007$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gupta, Satish</creatorcontrib><creatorcontrib>Jaworska-Bieniek, Katarzyna</creatorcontrib><creatorcontrib>Lubiński, Jan</creatorcontrib><creatorcontrib>Jakubowska, Anna</creatorcontrib><title>Can selenium be a modifier of cancer risk in CHEK2 mutation carriers?</title><title>Mutagenesis</title><addtitle>MUTAGE</addtitle><addtitle>Mutagenesis</addtitle><description>Selenium is an essential trace element for humans, playing an important role in various major metabolic pathways. Selenium helps to protect the body from the poisonous effects of heavy metals and other harmful substances. Medical studies have provided evidence of selenium supplementation in preventing certain cancers. Low and too high selenium (Se) status correlates with increased risk of e.g. lung, larynx, colorectal and prostate cancers. A higher level of selenium and supplementation with selenium has been shown to be associated with substantially reduced cancer mortality. Selenium exerts its biological roles through selenoproteins, which are involved in oxidoreductions, redox signalling, antioxidant defence, thyroid hormone metabolism and immune responses. Checkpoint kinase 2 (CHEK2) is an important signal transducer of cellular responses to DNA damage and acts as a tumour suppressor gene. Mutations in the CHEK2 gene have been shown to be associated with increased risks of several cancers. Four common mutations in CHEK2 gene (1100delC, IVS2+1G>A, del5395 and I157T) have been identified in the Polish population. Studies have provided evidence that CHEK2-truncating and/or missense mutations are associated with increased risk of breast, prostate, thyroid, colon and kidney cancers. The variability in penetrance and cancer expression in CHEK2 mutation carriers can probably be explained by the influence of other genetic or environmental factors. One of the possible candidates is Se, which together with genetic variations in selenoprotein genes may influence susceptibility to cancer risk.</description><subject>Checkpoint Kinase 2 - genetics</subject><subject>Checkpoint Kinase 2 - metabolism</subject><subject>Dietary Supplements</subject><subject>Humans</subject><subject>Mutation</subject><subject>Neoplasms - enzymology</subject><subject>Neoplasms - genetics</subject><subject>Neoplasms - prevention & control</subject><subject>Selenium - administration & dosage</subject><subject>Selenium - physiology</subject><subject>Selenoproteins - metabolism</subject><subject>Signal Transduction</subject><issn>0267-8357</issn><issn>1464-3804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNqFkD1PwzAURS0EoqUwsiKPLKHP38mEUFQoohILzJGT2JUhiYudDPz7pkqBkek96R7dKx2ErgncEcjYsh16vTXLrelBwAmaEy55wlLgp2gOVKokZULN0EWMHwBEUQnnaEY5AQmg5miV6w5H05jODS0uDda49bWzzgTsLa50V41fcPETuw7n69ULxYfJ3vluTEMYwXh_ic6sbqK5Ot4Fen9cveXrZPP69Jw_bJKKiaxPjKrLkhOiM6ZLbtJaU8mrGkimKqtVSaxIpbSCq5pxRQkXlo2pyEpdp5RatkC3U-8u-K_BxL5oXaxM0-jO-CEWhGdUUuCCjWgyoVXwMQZji11wrQ7fBYHiYK6YzBWTuZG_OVYPZWvqX_pH1d-2H3b_dO0BInh35Q</recordid><startdate>201311</startdate><enddate>201311</enddate><creator>Gupta, Satish</creator><creator>Jaworska-Bieniek, Katarzyna</creator><creator>Lubiński, Jan</creator><creator>Jakubowska, Anna</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U1</scope><scope>7U2</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>201311</creationdate><title>Can selenium be a modifier of cancer risk in CHEK2 mutation carriers?</title><author>Gupta, Satish ; Jaworska-Bieniek, Katarzyna ; Lubiński, Jan ; Jakubowska, Anna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c359t-e7dbb411a93ab4e8da264cd0197cfa7b1f5866f547d3472145f3d0159bad822f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Checkpoint Kinase 2 - genetics</topic><topic>Checkpoint Kinase 2 - metabolism</topic><topic>Dietary Supplements</topic><topic>Humans</topic><topic>Mutation</topic><topic>Neoplasms - enzymology</topic><topic>Neoplasms - genetics</topic><topic>Neoplasms - prevention & control</topic><topic>Selenium - administration & dosage</topic><topic>Selenium - physiology</topic><topic>Selenoproteins - metabolism</topic><topic>Signal Transduction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gupta, Satish</creatorcontrib><creatorcontrib>Jaworska-Bieniek, Katarzyna</creatorcontrib><creatorcontrib>Lubiński, Jan</creatorcontrib><creatorcontrib>Jakubowska, Anna</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Risk Abstracts</collection><collection>Safety Science and Risk</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Mutagenesis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gupta, Satish</au><au>Jaworska-Bieniek, Katarzyna</au><au>Lubiński, Jan</au><au>Jakubowska, Anna</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Can selenium be a modifier of cancer risk in CHEK2 mutation carriers?</atitle><jtitle>Mutagenesis</jtitle><stitle>MUTAGE</stitle><addtitle>Mutagenesis</addtitle><date>2013-11</date><risdate>2013</risdate><volume>28</volume><issue>6</issue><spage>625</spage><epage>629</epage><pages>625-629</pages><issn>0267-8357</issn><eissn>1464-3804</eissn><abstract>Selenium is an essential trace element for humans, playing an important role in various major metabolic pathways. Selenium helps to protect the body from the poisonous effects of heavy metals and other harmful substances. Medical studies have provided evidence of selenium supplementation in preventing certain cancers. Low and too high selenium (Se) status correlates with increased risk of e.g. lung, larynx, colorectal and prostate cancers. A higher level of selenium and supplementation with selenium has been shown to be associated with substantially reduced cancer mortality. Selenium exerts its biological roles through selenoproteins, which are involved in oxidoreductions, redox signalling, antioxidant defence, thyroid hormone metabolism and immune responses. Checkpoint kinase 2 (CHEK2) is an important signal transducer of cellular responses to DNA damage and acts as a tumour suppressor gene. Mutations in the CHEK2 gene have been shown to be associated with increased risks of several cancers. Four common mutations in CHEK2 gene (1100delC, IVS2+1G>A, del5395 and I157T) have been identified in the Polish population. Studies have provided evidence that CHEK2-truncating and/or missense mutations are associated with increased risk of breast, prostate, thyroid, colon and kidney cancers. The variability in penetrance and cancer expression in CHEK2 mutation carriers can probably be explained by the influence of other genetic or environmental factors. One of the possible candidates is Se, which together with genetic variations in selenoprotein genes may influence susceptibility to cancer risk.</abstract><cop>UK</cop><pub>Oxford University Press</pub><pmid>24106007</pmid><doi>10.1093/mutage/get050</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0267-8357 |
ispartof | Mutagenesis, 2013-11, Vol.28 (6), p.625-629 |
issn | 0267-8357 1464-3804 |
language | eng |
recordid | cdi_proquest_miscellaneous_1492620453 |
source | Oxford Journals Online |
subjects | Checkpoint Kinase 2 - genetics Checkpoint Kinase 2 - metabolism Dietary Supplements Humans Mutation Neoplasms - enzymology Neoplasms - genetics Neoplasms - prevention & control Selenium - administration & dosage Selenium - physiology Selenoproteins - metabolism Signal Transduction |
title | Can selenium be a modifier of cancer risk in CHEK2 mutation carriers? |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T18%3A15%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Can%20selenium%20be%20a%20modifier%20of%20cancer%20risk%20in%20CHEK2%20mutation%20carriers?&rft.jtitle=Mutagenesis&rft.au=Gupta,%20Satish&rft.date=2013-11&rft.volume=28&rft.issue=6&rft.spage=625&rft.epage=629&rft.pages=625-629&rft.issn=0267-8357&rft.eissn=1464-3804&rft_id=info:doi/10.1093/mutage/get050&rft_dat=%3Cproquest_cross%3E1492620453%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c359t-e7dbb411a93ab4e8da264cd0197cfa7b1f5866f547d3472145f3d0159bad822f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1492620453&rft_id=info:pmid/24106007&rft_oup_id=10.1093/mutage/get050&rfr_iscdi=true |